Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2011-06, Vol.34 (6), p.1424-1430 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1430 |
---|---|
container_issue | 6 |
container_start_page | 1424 |
container_title | Diabetes care |
container_volume | 34 |
creator | Eckel, Robert H Kahn, Steven E Ferrannini, Ele Goldfine, Allison B Nathan, David M Schwartz, Michael W Smith, Robert J Smith, Steven R |
description | OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management. |
doi_str_mv | 10.2337/dc11-0447 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3114323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A259679468</galeid><sourcerecordid>A259679468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</originalsourceid><addsrcrecordid>eNp90l2LEzEUBuAgilurF_4BHRBRL2bN12QSL5S1fi0s7oVbvAxnkjPdyDRTJ9OF-utNt3V1oUgIgZznZIaXQ8hjRo-5EPVr7xgrqZT1HTJhRlRlVUl9l0wok6asjOFH5EFKPyjNRuv75IgzRbkUbELm5w2mMG4KiL642Kyw4MWHAA2OmN4U3y9hLGYQi_dYzGNoA_preH3_FdGnYuy3xdPow1Xwa-jCL_TvHpJ7LXQJH-3PKZl_-ngx-1KenX8-nZ2cla5SaiwFqqppwNVSUEEV1UpxV4kWW4eycZICgpKG5hID0Ea1pvJeN5LT2mkmxZS83b27WjdL9A7jOEBnV0NYwrCxPQR7uxLDpV30V1aw3J2zm5IX-weG_uca02iXITnsOojYr5PVShtjqDFZvvyvZJQxTnOudabPdnQBHdoQ2z5_2225PeGVUbWRSmdVHlALjJh_tI_Yhnx9yx8f8Hl5XAZ3sOHVrsENfUoDtje5MGq3c2O3c2O3c5Ptk3-DvJF_BiWD53sAyUHXDhBdSH-dzEtTld3TnWuht7AYspl_y7lImjfXtRK_AcUPz3Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011201607</pqid></control><display><type>article</type><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R</creator><creatorcontrib>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R ; European Association for the Study of Diabetes ; American Diabetes Association ; Endocrine Society</creatorcontrib><description>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc11-0447</identifier><identifier>PMID: 21602431</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Animals ; Anti-Obesity Agents - therapeutic use ; attitudes and opinions ; Bariatric Surgery ; Behavior Therapy ; Biological and medical sciences ; blood glucose ; clinical trials ; cost effectiveness ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - etiology ; Diabetes Mellitus, Type 2 - genetics ; Diabetes. Impaired glucose tolerance ; drugs ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; experts ; genetics ; Humans ; Hypoglycemic Agents - therapeutic use ; insulin resistance ; Insulin Resistance - physiology ; Insulin-Secreting Cells - physiology ; lifestyle ; Medical sciences ; Metabolic diseases ; Miscellaneous ; noninsulin-dependent diabetes mellitus ; Obesity ; Obesity - complications ; Obesity - drug therapy ; Obesity - genetics ; Obesity - physiopathology ; pathogenesis ; pathophysiology ; patient care ; patients ; Pharmaceutical industry ; Prevention ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Reviews/Commentaries/ADA Statements ; Risk Factors ; Type 2 diabetes ; Weight Loss</subject><ispartof>Diabetes care, 2011-06, Vol.34 (6), p.1424-1430</ispartof><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 American Diabetes Association</rights><rights>2011 by the American Diabetes Association and The Endocrine Society. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</citedby><cites>FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,309,310,314,776,780,785,786,881,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24242806$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21602431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Eckel, Robert H</creatorcontrib><creatorcontrib>Kahn, Steven E</creatorcontrib><creatorcontrib>Ferrannini, Ele</creatorcontrib><creatorcontrib>Goldfine, Allison B</creatorcontrib><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Schwartz, Michael W</creatorcontrib><creatorcontrib>Smith, Robert J</creatorcontrib><creatorcontrib>Smith, Steven R</creatorcontrib><creatorcontrib>European Association for the Study of Diabetes</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><creatorcontrib>Endocrine Society</creatorcontrib><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</description><subject>Animals</subject><subject>Anti-Obesity Agents - therapeutic use</subject><subject>attitudes and opinions</subject><subject>Bariatric Surgery</subject><subject>Behavior Therapy</subject><subject>Biological and medical sciences</subject><subject>blood glucose</subject><subject>clinical trials</subject><subject>cost effectiveness</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - etiology</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>drugs</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>experts</subject><subject>genetics</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>insulin resistance</subject><subject>Insulin Resistance - physiology</subject><subject>Insulin-Secreting Cells - physiology</subject><subject>lifestyle</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>noninsulin-dependent diabetes mellitus</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Obesity - genetics</subject><subject>Obesity - physiopathology</subject><subject>pathogenesis</subject><subject>pathophysiology</subject><subject>patient care</subject><subject>patients</subject><subject>Pharmaceutical industry</subject><subject>Prevention</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Reviews/Commentaries/ADA Statements</subject><subject>Risk Factors</subject><subject>Type 2 diabetes</subject><subject>Weight Loss</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90l2LEzEUBuAgilurF_4BHRBRL2bN12QSL5S1fi0s7oVbvAxnkjPdyDRTJ9OF-utNt3V1oUgIgZznZIaXQ8hjRo-5EPVr7xgrqZT1HTJhRlRlVUl9l0wok6asjOFH5EFKPyjNRuv75IgzRbkUbELm5w2mMG4KiL642Kyw4MWHAA2OmN4U3y9hLGYQi_dYzGNoA_preH3_FdGnYuy3xdPow1Xwa-jCL_TvHpJ7LXQJH-3PKZl_-ngx-1KenX8-nZ2cla5SaiwFqqppwNVSUEEV1UpxV4kWW4eycZICgpKG5hID0Ea1pvJeN5LT2mkmxZS83b27WjdL9A7jOEBnV0NYwrCxPQR7uxLDpV30V1aw3J2zm5IX-weG_uca02iXITnsOojYr5PVShtjqDFZvvyvZJQxTnOudabPdnQBHdoQ2z5_2225PeGVUbWRSmdVHlALjJh_tI_Yhnx9yx8f8Hl5XAZ3sOHVrsENfUoDtje5MGq3c2O3c2O3c5Ptk3-DvJF_BiWD53sAyUHXDhBdSH-dzEtTld3TnWuht7AYspl_y7lImjfXtRK_AcUPz3Y</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Eckel, Robert H</creator><creator>Kahn, Steven E</creator><creator>Ferrannini, Ele</creator><creator>Goldfine, Allison B</creator><creator>Nathan, David M</creator><creator>Schwartz, Michael W</creator><creator>Smith, Robert J</creator><creator>Smith, Steven R</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110601</creationdate><title>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</title><author>Eckel, Robert H ; Kahn, Steven E ; Ferrannini, Ele ; Goldfine, Allison B ; Nathan, David M ; Schwartz, Michael W ; Smith, Robert J ; Smith, Steven R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-3e65bbac743030608662c53fefce4bc40aea64900601aa896f95dd8b4207c8143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Animals</topic><topic>Anti-Obesity Agents - therapeutic use</topic><topic>attitudes and opinions</topic><topic>Bariatric Surgery</topic><topic>Behavior Therapy</topic><topic>Biological and medical sciences</topic><topic>blood glucose</topic><topic>clinical trials</topic><topic>cost effectiveness</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - etiology</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>drugs</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>experts</topic><topic>genetics</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>insulin resistance</topic><topic>Insulin Resistance - physiology</topic><topic>Insulin-Secreting Cells - physiology</topic><topic>lifestyle</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>noninsulin-dependent diabetes mellitus</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Obesity - genetics</topic><topic>Obesity - physiopathology</topic><topic>pathogenesis</topic><topic>pathophysiology</topic><topic>patient care</topic><topic>patients</topic><topic>Pharmaceutical industry</topic><topic>Prevention</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Reviews/Commentaries/ADA Statements</topic><topic>Risk Factors</topic><topic>Type 2 diabetes</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Eckel, Robert H</creatorcontrib><creatorcontrib>Kahn, Steven E</creatorcontrib><creatorcontrib>Ferrannini, Ele</creatorcontrib><creatorcontrib>Goldfine, Allison B</creatorcontrib><creatorcontrib>Nathan, David M</creatorcontrib><creatorcontrib>Schwartz, Michael W</creatorcontrib><creatorcontrib>Smith, Robert J</creatorcontrib><creatorcontrib>Smith, Steven R</creatorcontrib><creatorcontrib>European Association for the Study of Diabetes</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><creatorcontrib>Endocrine Society</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Eckel, Robert H</au><au>Kahn, Steven E</au><au>Ferrannini, Ele</au><au>Goldfine, Allison B</au><au>Nathan, David M</au><au>Schwartz, Michael W</au><au>Smith, Robert J</au><au>Smith, Steven R</au><aucorp>European Association for the Study of Diabetes</aucorp><aucorp>American Diabetes Association</aucorp><aucorp>Endocrine Society</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>34</volume><issue>6</issue><spage>1424</spage><epage>1430</epage><pages>1424-1430</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>OBJECTIVE: This report examines what is known about the relationship between obesity and type 2 diabetes and how future research in these areas might be directed to benefit prevention, interventions, and overall patient care. RESEARCH DESIGN AND METHODS: An international working group of 32 experts in the pathophysiology, genetics, clinical trials, and clinical care of obesity and/or type 2 diabetes participated in a conference held on 6-7 January 2011 and cosponsored by The Endocrine Society, the American Diabetes Association, and the European Association for the Study of Diabetes. A writing group comprising eight participants subsequently prepared this summary and recommendations. Participants reviewed and discussed published literature and their own unpublished data. RESULTS: The writing group unanimously supported the summary and recommendations as representing the working group's majority or unanimous opinions. CONCLUSIONS: The major questions linking obesity to type 2 diabetes that need to be addressed by combined basic, clinical, and population-based scientific approaches include the following: 1) Why do not all patients with obesity develop type 2 diabetes? 2) Through what mechanisms do obesity and insulin resistance contribute to β-cell decompensation, and if/when obesity prevention ensues, how much reduction in type 2 diabetes incidence will follow? 3) How does the duration of type 2 diabetes relate to the benefits of weight reduction by lifestyle, weight-loss drugs, and/or bariatric surgery on β-cell function and glycemia? 4) What is necessary for regulatory approval of medications and possibly surgical approaches for preventing type 2 diabetes in patients with obesity? Improved understanding of how obesity relates to type 2 diabetes may help advance effective and cost-effective interventions for both conditions, including more tailored therapy. To expedite this process, we recommend further investigation into the pathogenesis of these coexistent conditions and innovative approaches to their pharmacological and surgical management.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>21602431</pmid><doi>10.2337/dc11-0447</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-5992 |
ispartof | Diabetes care, 2011-06, Vol.34 (6), p.1424-1430 |
issn | 0149-5992 1935-5548 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3114323 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
subjects | Animals Anti-Obesity Agents - therapeutic use attitudes and opinions Bariatric Surgery Behavior Therapy Biological and medical sciences blood glucose clinical trials cost effectiveness Diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - etiology Diabetes Mellitus, Type 2 - genetics Diabetes. Impaired glucose tolerance drugs Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance experts genetics Humans Hypoglycemic Agents - therapeutic use insulin resistance Insulin Resistance - physiology Insulin-Secreting Cells - physiology lifestyle Medical sciences Metabolic diseases Miscellaneous noninsulin-dependent diabetes mellitus Obesity Obesity - complications Obesity - drug therapy Obesity - genetics Obesity - physiopathology pathogenesis pathophysiology patient care patients Pharmaceutical industry Prevention Public health. Hygiene Public health. Hygiene-occupational medicine Reviews/Commentaries/ADA Statements Risk Factors Type 2 diabetes Weight Loss |
title | Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T00%3A21%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Obesity%20and%20Type%202%20Diabetes:%20What%20Can%20Be%20Unified%20and%20What%20Needs%20to%20Be%20Individualized?&rft.jtitle=Diabetes%20care&rft.au=Eckel,%20Robert%20H&rft.aucorp=European%20Association%20for%20the%20Study%20of%20Diabetes&rft.date=2011-06-01&rft.volume=34&rft.issue=6&rft.spage=1424&rft.epage=1430&rft.pages=1424-1430&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc11-0447&rft_dat=%3Cgale_pubme%3EA259679468%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1011201607&rft_id=info:pmid/21602431&rft_galeid=A259679468&rfr_iscdi=true |